About Impetis
Impetis is a Healthcare company based in Mumbai (India) founded in 2016. Drug discovery and licensing for auto-immune, inflammatory, and oncology treatments via partnerships. It operates on a B2B model. The company has 2 employees. Its Indian entity Impetis Biosciences Limited reported revenue of ₹1.48 Cr. Impetis offers products and services including Adenosine Receptor Antagonists, JAK Inhibitors, BTK Inhibitors, Glucokinase Receptor Activator, and Early Stage Programs. Its focus areas include Biotechnology, Drug Discovery, Preclinical Development and Oncology.
Company details
Impetis Biosciences focuses on discovering and developing innovative drug candidates, including inhibitors and activators, for treating auto-immune, inflammatory diseases, and immuno-oncology conditions. The company advances these assets through preclinical programs and seeks collaborations with partners to bring treatments to patients with limited options. Founded in 2017, it operates from Mumbai, India, aiming to transform lives by addressing unmet medical needs in healthcare.
- Headquarters Mumbai, India
- Employees 2
- SectorsHealthcare
- Website impetisbiosciences.com
- Legal Name Impetis Biosciences Limited
- Date of Incorporation 29 May, 2017
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹1.48 Cr
FY 2026 · -8% YoY
- Net Profit₹85,575
FY 2026 · 1% margin
- EBITDA₹1.16 Cr
FY 2026 · 78% margin
- Employee Count2
Associated legal entities of Impetis
Impetis operates through Impetis Biosciences Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Impetis Biosciences Limited CIN U74999MH2017PLC295474 | Active | 29 May 2017 | Mumbai, Maharashtra | ₹1.5 Cr | 2 | 3 | View details |
Products & Services of Impetis
Impetis offers a comprehensive portfolio of products and services, including Adenosine Receptor Antagonists, JAK Inhibitors, BTK Inhibitors, Glucokinase Receptor Activator, and Early Stage Programs.
Inhibitor targeting auto-immune and inflammatory diseases in preclinical stage.
Therapy for auto-immune conditions through immune response modulation.
Treatment option for inflammatory diseases and oncology applications.
Activator for potential metabolic and inflammatory disorder management.
Preclinical initiatives for various therapeutic indications in healthcare.
Board of directors of Impetis Biosciences Limited (Impetis)
Impetis Biosciences Limited is the primary company behind Impetis. The board of Impetis Biosciences Limited currently have 3 directors; the longest-serving is Abhishek Jain, appointed in 2024. 7 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Abhishek Jain DIN 10528511 | Director | 04 Mar 2024 | 2 yrs 7 mo | Impetis Biosciences Limited |
| Tarun Dayal Bhojwani DIN 09809233 | Director | 16 Jan 2025 | 1 yr 9 mo | Impetis Biosciences Limited |
| Shaurya Nemish Mehta DIN 05129792 | Additional Director | 29 Jun 2026 | 4 mo | Impetis Biosciences Limited |
Financials of Impetis
Figures of Impetis Biosciences Limited, the primary company behind Impetis, for FY 2026. Revenue was ₹1.48 Cr (-8% year on year). Net profit was ₹85,575 (1% margin). EBITDA was ₹1.16 Cr (78% margin). Revenue has grown at a compounded annual rate of -45% over three years and -26% over five years.
- ₹1.48 CrRevenue · FY 2026 · -8% YoY
- ₹85,575Net profit · 1% margin
- ₹1.16 CrEBITDA · 78% margin
- ₹3.73 CrPaid-up capital
- 2Employees (provident fund records)
- -45%Revenue CAGR, 3 years
- -26%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Impetis Biosciences Limited are on its company page.
Detailed financial statements for Impetis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Impetis (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Impetis
Impetis was founded in 2016.
Impetis is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Impetis has 2 employees.
The primary company behind Impetis, Impetis Biosciences Limited, reported revenue of ₹1.48 Cr for FY 2026, down 8% year on year.
Impetis Biosciences focuses on discovering and developing innovative drug candidates, including inhibitors and activators, for treating auto-immune, inflammatory diseases, and immuno-oncology conditions. The company advances these assets through preclinical programs and seeks collaborations with partners to bring treatments to patients with limited options. Founded in 2017, it operates from Mumbai, India, aiming to transform lives by addressing unmet medical needs in healthcare.
Impetis offers Adenosine Receptor Antagonists, JAK Inhibitors, BTK Inhibitors, Glucokinase Receptor Activator, and Early Stage Programs.
Impetis operates through Impetis Biosciences Limited.
The legal entities of Impetis currently have 3 directors, including Tarun Dayal Bhojwani, Abhishek Jain, Shaurya Nemish Mehta.